High-dose rate interstitial brachytherapy for stage I-II tongue cancer

Umeda, Masahiro; Komatsubara, Hideki; Nishimatsu, Naruki; Yokoo, Satoshi; Shibuya, Yasuyuki; Komori, Takahide

doi:10.1067/moe.2000.110087

Cited by 30 publications

(22 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HDR brachytherapy has become prevalent in the treatment of oral cancer and it is as safe as LDR brachytherapy [18,26], but there are few studies especially on reirradiation cases like a postbrachytherapy group in this study. LDR brachytherapy may be more appropriate, because there is a greater difference in radiation tolerance between normal mucous membrane and tumor than with HDR brachytherapy [27,28]. As for the better dose rate used for reirradiation, further studies are necessary.…”

Section: Discussionmentioning

confidence: 99%

Curative Brachytherapy for Recurrent/Residual Tongue Cancer

Ayukawa

Shibuya²,

Yoshimura³

et al. 2007

Strahlenther Onkol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Curative Brachytherapy for Recurrent/Residual Tongue Cancer

Ayukawa

Shibuya²,

Yoshimura³

et al. 2007

Strahlenther Onkol

View full text Add to dashboard Cite

show abstract

“…5 Lau et al 6 , however, reported a loss of therapeutic ratio with 6.5 Gy twice daily for 7 fractions. Umeda et al 7 also reported an inferior local control with HDR treatment when it was compared with a historical control group that was treated with traditional LDR brachytherapy. Both groups cautioned against the use of HDR brachytherapy until further studies are done.…”

mentioning

confidence: 94%

High dose rate brachytherapy for early stage oral tongue cancer

et al. 2002

View full text Add to dashboard Cite

show abstract

“…The late effects may include xerostomia resulting in dry mouth, speech and swallowing difficulty, dental caries. Stricture formation, ulceration and necrosis can also occur in late stage [18].…”

Section: Resultsmentioning

confidence: 99%

Iridium Implantation in T1 and T2 Cancers of Anterior Tongue: Report from B. P. Koirala Memorial Cancer Hospital, Nepal

Vijayakumar¹,

Acharya²,

Prasad³

et al. 2012

IJMPCERO

View full text Add to dashboard Cite

Early stage cancers of tongue are treated traditionally with a wide local excision or hemiglossectomy, but the preservation of normal speech and swallowing are hampered. Most of the patients are treated with external beam irradiation to achieve the best locoregional control as only a limited number of tongue cancers can be excised. Underdeveloped nations with finite resources are still dependent on cobalt based external beam radiotherapy and sometimes a Linear Accelerator with two dimensional planning. This treatment has many limitations, as the large radiation fields irradiate not only the tumor but also normal tissue. The sequalae include mucositis, dry mouth, teeth and gum injury, spinal cord damage and rarely mandibular necrosis. Intensity modulated radiotherapy, which can abrogate these side effects, is not available to these patients. Irradiation using implanted solid radioactive sources into the tumor tissue is a viable option in this context. This kind of treatment is termed as brachytherapy and if the implant is introduced into the tissue then it is interstitial brachytherapy. This report details our experience in interstitial implantation, planning, dosimetry and treatment. Diagnosed cancers of anterior 2/3rd of lateral border of tongue with T1 N0M0 or T2 N0M0 stages were subjected to Iridium implantation under general anesthesia. Orthogonal films were taken and planning done with brachyvision treatment planning system. High dose rate radiotherapy was delivered as per the prescription. Excellent local control of the tumor was achieved with no undue morbidity to the adjacent structures. The patients were asked to undergo regular follow up. Surgical salvage was advised in cases of nodal recurrence. Interstitial implantation is a treatment that can be safely administered in early stage cancers of the tongue. This has remarkable efficacy and is also a patient friendly procedure.

show abstract

High-dose rate interstitial brachytherapy for stage I-II tongue cancer

Cited by 30 publications

References 7 publications

Curative Brachytherapy for Recurrent/Residual Tongue Cancer

Curative Brachytherapy for Recurrent/Residual Tongue Cancer

High dose rate brachytherapy for early stage oral tongue cancer

Iridium Implantation in T1 and T2 Cancers of Anterior Tongue: Report from B. P. Koirala Memorial Cancer Hospital, Nepal

Contact Info

Product

Resources

About